#### CG020 Genomics Lesson 11

#### **Genomics – practical applications**

#### Markéta Pernisová

#### Functional Genomics and Proteomics of Plants,

Mendel Centre for Plant Genomics and Proteomics, CEITEC - Central European Institute of Technology, Masaryk Univerzity, Brno marketa.pernisova@ceitec.muni.cz, <u>www.ceitec.muni.cz</u>







Tato prezentace je spolufinancována Evropským sociálním fondem a státním rozpočtem České republiky

#### Outline

- 1. Genomics in medicine
- 2. Biotechnology
- 3. Genetically modified organisms
- 4. GMO pros and cons
- 5. Discussion



- Biotechnology and gene technology are crucial technologies in medicine
- Improvement in practice:
  - faster identification and analysis of new pathogens
  - faster development and production of vaccines and reliable diagnostic tools
  - genetic tests for screening of heritable diseases or severe genetic defects in the embryo or foetus
- many drugs produced in laboratories:
  - bacteria, yeast and mammalian cell cultures produce human proteins available as drugs
  - developing of e.g. edible vaccines produced by transgenic plants
  - 1<sup>st</sup> biotech drug: insulin, 1982

- Influence of genomics on medicine:
  - knowledge of the genome can lead to understanding the origin of disease - mutant gene – misfunction of the protein
  - knowledge of the gene will allow screening for the disease
  - understanding gene influence on drug effects and origin of side effects
  - assessing individual genetic predisposition becomes possible
  - improving the effectiveness of new approaches to cure diseases
  - knowledge of bacterial and viral genomes helps easier identification of the mechanism of infection and improve prevention, treatment, as well as accelerate vaccine development
  - genome research is helping us better understand the aging process and improving the quality of life for older people

- The use of genomics in medicine:
  - genetic diagnosis
  - individualized medicine
  - gene therapy
  - regenerative medicine
  - xenotransplantation
  - molecular *in vitro* systems to study human diseases



# **GENETIC DIAGNOSIS**

- test performed to identify specific genetic traits of an individual
- do not need to know the sequence of the entire genome
- used for:
  - clarifying whether a disease appeared as a result of changes in specific genetic traits
  - confirming and refining standard medical diagnosis of an already apparent disease
  - identification of hereditary diseases before they become evident
  - pre-implantation screens of embryos fertilized *in vitro*
  - assessment of individual predispositions of a person for developing certain diseases later in life
  - DNA fingerprinting in criminal investigations and paternity disputes

The medical approach that emphasizes the systematic use of information specific to an individual patient to set up an optimized preventive and therapeutic plan for each patient.

- Presumptions:
  - detailed knowledge of the genome of the patient, ideally the entire genome sequence
  - knowledge of the function of individual genes, including functional differences of individual alleles represented in the population
  - correlation of sequences with the prognosis of the disease, and with the success rate of therapeutic procedures ...

- uses knowledge of the genome for:
  - prediction of health risks
  - diagnosis
  - selection of the most appropriate type of treatment
  - minimizing the side effects of treatment
  - prevention





#### PERCENTAGE OF THE PATIENT POPULATION FOR WHICH A PARTICULAR DRUG IS INEFFECTIVE, ON AVERAGE

ANTI-DEPRESSANTS (SSRIs)	38%
ASTHMA DRUGS	<b>40%</b>
DIABETES DRUGS	43%
ARTHRITIS DRUGS	50%
ALZHEIMER'S DRUGS	70%
CANCER DRUGS	75%



• Just in hospitals: about 6.7% of patients (2.2 million) experience serious adverse drug reactions



Serious adverse drug reactions in even smaller percentages of treated populations have led to the withdrawal of several drugs from the market

Zelnorm

Cylert

"Are good drugs going to the wrong people?"

Vioxx

Baycol

Rezulin

Lotronex\*

Source of data: Brian B. Spear, Margo Heath-Chiozzi, Jeffery Huff, "Clinical Trends in Molecular Medicine," Volume 7, Issue 5, 1 May 2001, Pages 201-204.



- Problem:
  - multigene conditionality of most human diseases



Goh et al., 2007

- Problem-solving:
  - systems biology uses e.g. gene clustering to identify genes involved in the observed phenomenon



- Problem-solving :
  - biomarkers
  - tests

**Table:** Selected Personalized Medicine Drugs, Treatments and Diagnostics as of September 2011\*

Indications in quotes and otherwise unattributed, are cited from the therapeutic or diagnostic product label.

Therapeutic product labels contain pharmacogenomic information as:

Information only

Recommended

Required

Unhighlighted products have no pharmacogenomic information, recommendations or requirements in the label.

THERAPY	<b>BIOMARKER/TEST</b>	INDICATION
Mivacron® (mivacurium)	Cholinesterase gene	Anesthesia adjunct: "Mivacron is metabolized by plasma cholinesterase and should be used with great caution, if at all, in patients known to be or suspected of being homozygous for the atypical plasma cholinesterase gene."
Ansaid® (flurbiprofen)	CYP2C9	Arthritis: "In vitro studies have demonstrated that cytochrome P450 2C9 plays an important role in the metabolism of flurbiprofen to its major metabolite, 4'-hydroxy-flurbiprofen."
Depakote® (divalproex)	UCD (NAGS; CPS; ASS; OTC; ASL; ARG)	Bipolar disorder: "Hyperammonemic encephalopathy, sometimes fatal, has been reported following initiation of valproate therapy in patients with urea cycle disorders [UCDs]particularly ornithine transcarbamylase deficiency [OTC]."
Aromasin® (exemestane) Arimidex® (anastrozole) Nolvaldex® (tamoxifen)	Estrogen Receptor (ER)	Breast cancer: Exemestane is indicated for adjuvant treatment of post- menopausal women with ER-positive early breast cancer. Anastrozole is for treatment of breast cancer after surgery and for metastases in post-menopausal women. Tamoxifen is the standard therapy for estrogen receptor-positive early breast cancer in pre-menopausal women.
Chemotherapy	Mammostrat <sup>∞</sup>	Breast cancer: Prognostic immunohistochemistry (IHC) test used for postmenopausal, node negative, estrogen receptor expressing breast cancer patients who will receive hormonal therapy and are considering adjuvant chemotherapy.
Chemotherapy	MammaPrint®	Breast cancer: Assesses risk of distant metastasis in a 70-gene expression profile.
Chemotherapy	Onco <i>type</i> DX <sup>®</sup> 16-gene signature	Breast cancer: A 16-gene signature (plus five reference genes) indicates whether a patient has a low, intermediate, or high risk of having a tumor return within 10 years. Low-risk patients may be treated successfully with hormone therapy alone. High-risk patients may require more aggressive treatment with chemotherapy.
Chemotherapy	CompanDx® 31-gene signature	Breast cancer: The test predicts "time to event" for metastasis of breast cancer, following surgery or biopsy.
Faslodex® (fulvestrant)	Hormone Receptor (HR)	Breast cancer: Fulvestrant is indicated for the treatment of hormone receptor positive metastatic breast cancer in post-menopausal women with disease progression following anti-estrogen therapy.
Herceptin® (trastuzumab) Tykerb® (lapatinib)	HER-2/neu receptor	Breast cancer: "for the treatment of patients with metastatic breast cancer whose tumors overexpress the HER-2 [Human Epidermal growth factor Receptor 2] protein and who have received one or more chemotherapy regimens for their metastatic disease." High levels of HER-2 expression have been associated with increased disease recurrence in breast cancer, but show a better response to trastuzumab.
Pharmaceutical and surgical prevention options and surveillance	BRCA 1/2	Breast cancer: Guides surveillance and preventive treatment based on susceptibility risk for breast and ovarian cancer.
Nolvadex <sup>®</sup> (tamoxifen)	Breast Cancer Index <sup>™</sup> (HOXB13, IL17BR)	Breast cancer: Calculates a combined risk analysis for recurrence after tamoxifen treatment for ER-positive, node-negative breast cancer.

The Case for Personalized Medicine, 3rd edition

- Other problems
  - Ethical issues:
    - the condition is genetic testing or knowledge of the genome easily abused
    - risk: insufficient data security
    - in some countries, employers or insurance companies do not have access to such data
  - High costs risks:
    - medicine could be divided into first-class and low-class services
    - globalization gap could grow even larger poor countries would not be able to afford this
  - Privacy:
    - crucial and complex issue
    - what information about oneself can/should be considered private?

### **GENE THERAPY**

Procedure in which the DNA sequence is inserted into the patient genome to replace or supplement an original gene

- Options:
  - replace the mutated gene
  - repair the mutation
  - deliver DNA encoding a therapeutic protein
  - antisense therapy
- In the future useful for treating e.g. hereditary diseases
- Types:
  - somatic gene therapy
  - gene therapy of germ cells

# **GENE THERAPY**

- Methods:
  - viral vectors
    - retroviruses
    - adenoviruses
    - herpes simplex virus
    - vectors capable of replication
  - non-viral methods
    - injection of plasmid DNA into muscle
    - increased efficiency of DNA delivery:
      - electroporation
      - sonoporation
      - "gene gun"
      - magnetofection
  - hybrid methods



# **REGENERATIVE MEDICINE**

The aim is to **recover** diseased or injured **organs** or tissues.

- to overcome the problems of transplantation:
  - shortage of donors
  - risk of rejection
  - severe immunosuppresive course
- therapeutic cloning cell therapy that uses stem cells to produce healthy copies of cells/tissues of the patient
- potential medical applications: treatment of degenerative diseases such as Parkinson's disease, apoplexy, organ damage, diabetes, burns ...

#### **REGENERATIVE MEDICINE**

 embryonic stem cells from animals have been successfully programmed to develop into neural, muscle and other cells - promising results

Ethical issues: egg cell is used to form an embryo that does not develop into an organism. Instead, after 5-6 days of development, embryonic stem cells are extracted, which destroys the embryo. Depending on the definition of the point from which you must protect human life, it can be regarded as creating human life to destroy it, and is therefore prohibited.

 consequence of ethical debate: increased support for research on adult stem cells

- The use of genomics in medicine:
  - genetic diagnosis
  - individualized medicine
  - gene therapy
  - regenerative medicine
  - xenotransplantation
  - molecular *in vitro* systems to study human diseases



- It uses living organisms, cells or parts of cells (enzymes) for research, leading to new products and applications in medicine, agriculture, food, environmental protection
- Also used in developing better/sustainable production methods for the chemical industry and other industrial processes.
- An **interdisciplinary approach** requiring knowledge of chemistry, biology, physics, material sciences, engineering and informatics.
- The origin of biotechnology can be traced back 4,000 years, when the Sumerians (although not knowingly) used microbes for the production of alcoholic beverages.

- modern biotechnology often changes the genetic status of cells and organisms to optimize processes, e.g. by chemical or physical treatment, cell fusion or genetic engineering.
- genetic engineering modifies isolated nucleic acids
- concepts of modern biotechnology and genetic engineering are often used as synonyms
- genetic engineering is actually only one branch of the biotechnology industry
- genetic engineering GMO

- Examples:
  - effective utilization of plant biomass for fuel production
  - acquisition of starting material (monomers) for the production of polymers from living organisms instead of from fossil sources
  - phytopharmaceutics using plants to produce new vaccination methods such as expression of antibodies, or antigens suitable for immunization
- European Federation of Biotechnology



# **PLANT BIOTECHNOLOGY**

The Biorefinery platform using Agricultural Feed Stocks



# PLANT BIOTECHNOLOGY

- Examples:
  - production of spider filaments
  - production of degradable biopolymers
  - production of elastin-like polypeptides (component of animal tissues)
  - production of vaccines and antibodies:
    - human (HIV TNF)
    - animal (veterinary)
  - immunomodulation of plant hormones

#### FACTS TO THINK ABOUT



- Our civilization is built on farming, the surface area needed for feeding people has decreased by 90% over 10,000 years
- To prevent collapse, it is necessary to reduce this area from the current 0.45 ha/person to 0.2 ha/person by the year 2050
- Return to original methods of agriculture would be a return to the original demands on area and therefore would be unsustainable
- Intensive farming = conversion of water and oil into food
- The goal of plant biotechnology is to use all the available scientific knowledge to breed varieties with higher yield with lower inputs (of land, water, fertilizers, sprays ...)

#### **GENETICALLY MODIFIED ORGANISMS**



# BREEDING

to

- genetic basis of organisms naturally varies due to mutations
- before the era of genetic engineering question of chance
- breeding tools:
  - selection and crossing
- selection:
  - positive or negative
- results were incidental
- modern breeder learned change hereditary information
- chemicals, radiation ...



**Success** is not always visible at a glance

# **GENETIC ENGINEERING**

- Discovery of:
  - DNA structure (1953)
  - restriction enzymes
  - plasmids
- targeted change ("targeted breeding")
- 1973 bacteria produce frog protein
- recombinant DNA technology = "gene cut" = genetic engineering
- ability to transfer genes = transgenosis
- according to the law: genetic modification
- result: **GMO**
- the first practical application: production of human insulin in bacteria 1978



#### **BREEDING vs. GENETIC ENGINEERING**



#### GENETICALLY MODIFIED ORGANISMS (GMOs)

- Organisms carrying modified genetic information – either own or foreign (from another organism), enabling targeted changes in the organism and its use for specific purposes
- GMO:
  - plants
  - bacteria
  - animals

http://www.gmo-compass.org/

# **GMO PLANTS**

- Use:
  - resistance to pests
  - herbicide resistance
  - resistance to drought
  - resistance to cold
  - resistance to salinity
  - more efficient nitrogen utilization
  - increasing nutritional quality



http://ipbo.vib-ugent.be/

#### **Bt PLANTS**

- resistance to insect pests
- corn, cotton, rice
- genes from *Bacillus thuringiensis* (Bt)
- express delta-endotoxins (Cry proteins)
- increasing yields, reducing the amount of chemical sprays



Corn borer damage



European corn borer damage and fungal infection in non-Bt (left) and Bt hybrids (right)

# **Ht PLANTS**

- resistance to systemic herbicides
- glyphosate
  - interferes in the synthesis of aromatic amino acids; animals without the appropriate enzymatic apparatus = harmless
  - blocks the enzyme 5-enolpyrovylshikimate-3-phosphate synthase (EPSPS) in chloroplasts – affects green plants
  - ineffective for bacterial EPSPS evolutionarily divergent
  - soya, maize, sugar beet, canola, cotton, alfalfa added enzyme for tolerance
  - company Monsanto: Roundup
- glufosinate (phosphinothricin)
  - prevents processing of ammonium toxic
  - Streptomyces hygroscopicus synthesizes and transforms it: acetylation by the enzyme phosphinothricin acetyltransferase coding gene isolated in 1987 named bar
- trade names: Basta, Liberty, Finale, Radical ...
## **MULTIRESISTENT PLANTS**

- Bt resistance + herbicide
- multiresistant corn the majority of total production in the USA
- example of multiresistant corn:
  - three Bt genes for resistance to air pests
  - three Bt genes for resistance against soil pests
  - two genes for herbicide resistance

### **DISEASES TOLERANT PLANTS**

- viruses no chemical agents available
- gene encoding non-infectious viral envelope protein increases resistance to viral infection
- banana; papaya Hawaii, Southeast Asia
- cassava a basic food ingredient for more than 500 million people + animal feed



Left: Papaya with Papaya ringspot disease Right: Biotech Papaya resistant

#### **DROUGHT TOLERANT PLANTS**





New drought-tolerant maize (right) needs less water.

Drought in Ethiopia

- chickpeas more resistant to drought, but toxic
- corn resistant to drought: commercially utilizable in 2016

#### NITROGEN USAGE INCREASE

- use of nitrogen from fertilizers
- gene from barley 3x higher nitrogen utilization under oxygen deficiency



The effect of Nitrogen Use Efficiency (NUE) in rice growth with reduced N applications. Left: rice engineered

# **INCREASING NUTRITIONAL QUALITY**

- golden rice
  - several genes from maize encoding enzymes for the biosynthesis of βcarotene (precursor of vitamin A)
  - avoid problems with your eyes in a large part of the population in India and China
- canola and soybean
  - improved oil properties: stable, resistant to high temperatures, long storage



Golden Rice

#### **GMO ANIMALS**

- Transgenic cats
  - lentiviruses are sensitive to restriction factors
  - specific restriction factor: rhesus macaque TRIMCyp + eGFP
  - uniform expression, no mosaicity and no silencing in F1 generation
  - lymphocytes of transgenic animals resistant to replication of FIV





Wongsrikeao et al., 2011, Nature Methods

#### **GMO** plants lacksquare

increased yields without insecticides, pesticides, fungicides •



Jonas Kathage<sup>1</sup> and Matin Qaim<sup>1</sup>

Department of Agricultural Economics and Rural Development, Georg-August-University of Goettingen, D-37073 Goettingen, Germany

Edited by Calestous Juma, Harvard University, Cambridge, MA, and approved May 15, 2012 (received for review March 2, 2012)

Despite widespread adoption of genetically modified crops in many countries, heated controversies about their advantages and disadvantages continue. Especially for developing countries, there

successful farmers may have higher crop yields and profits anyway, this can result in inflated benefit estimates. Third, most available studies focus on agronomic impacts of Bt, such as yield

- 24% yield gain per acre
- 50% yield improvement for small farmers

Yield Gains from	
<b>Bt Maize</b>	<b>Bt</b> Cotton
5% U.S. & Canada	9.6% United States
6.3% Uruguay	11.8% Mexico
7.4% Spain	24.3% South Africa
7.8% Argentina	28.6% Argentina
15.3% South Africa	54.8% India
24.1% Philippines	

Viald Calma 6

Ohio State University, December 2011

#### GMO plants

- reduce pesticide use the negative impact of strong chemicals currently used in agriculture
- increase nitrogen utilization from mineral fertilizers the negative impact of excessive fertilizer use on water quality
- increase the nutritional quality of crops
- reduce cultivation area (increased yield per unit area)
- pollen transfer to other species (hybridization) was detected in frequencies between 0.05 to 0.53%

#### GMO plants

- Bt crops: negative impact on other than pest insects ???
- affect some butterflies and beetles
- more insects on Bt cotton



#### GMO plants

- risk of allergies
  - GMO plants always contain only one or a few transgenes and are very thoroughly tested
  - on the other hand, new varieties created using strong mutagens, e.g. X-rays are far less tested. With these methods tens or hundreds of new mutations occur at once
- ban on GMO cultivation in Switzerland was decided by referendum
- 30% of the EU population believes that the only transgenic plants have genes and refuse to eat them ...



Our task:

- tirelessly to explain the rational use of scientific knowledge, including genomics, it is necessary both for advances in medicine and for the preservation of our civilization
- discussions with the general public about the importance and benefits of GMOs for human society
- need to defend GMO plants crops for 21<sup>st</sup> century
- no technology is without risk, including GMOs, but there is not cause to demonize GMOs and target them
  financial benefit of some companies ...

#### LITERATURE

• see lecture





Biotechnology in Africa's Development Bacot of the High-Lawel African Panel on Midden Biotechnology

Colestous Juma | Ismail Serapelitis





Discussion